Although there are a number of vaccines available for influenza it is widely recognised there is a desperate need for new ones, see WHO report here and CDC site here
And in particular better vaccines are needed for more vulnerable groups, see link here

No other vaccine in use or in or approaching a clinical trial is being delivered to the lungs; this route of delivery differentiates our approach from the rest which are mainly by injection. Furthermore we have the advantage of low-dose vaccination which is inherently more boostable, more cost-effective, quicker to manufacture and more suitable for the logistical challenges of the developing world. Our approach provides cross protection against related strains and potentially many advantages over other potentially universal flu vaccines in development, see WHO link above.

Our vaccines are not capable of replication and are delivered to the lungs therefore they do not adversely affect immunity to bacteria in the lungs and are likely to be more effective with better cross protection.